Anti-amyloid antibodies against Alzheimer's disease : Lecanemab and donanemab in practice-Clinical importance, patient selection and safety management (PubMed, Nervenarzt) - Oct 10, 2026 - "Amyloid-related imaging abnormalities (ARIA) are the key adverse event, manageable through patient selection, ApoE-ε4 genotyping and magnetic resonance imaging (MRI) monitoring. The indications and follow-up belong in specialized centers."
Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • APOE
|